Abstract
Purpose
Vasovagal syncope is a common clinical condition that lacks effective medical therapies despite being associated with significant morbidity. Current guidelines suggest that serotonin-specific reuptake inhibitors might suppress vasovagal syncope but supporting studies have been small and heterogenous. The purpose of this study was to evaluate the efficacy of serotonin-specific reuptake inhibitors to prevent syncope in patients with recurrent vasovagal syncope by conducting a systematic review and meta-analysis of published studies.
Methods
Relevant randomized controlled trials were identified from the MEDLINE and Embase databases without language restriction from inception to August 2022, and ClinicalTrials.gov. All studies were conducted in clinical syncope populations and compared the benefit of serotonin versus placebo. Weighted relative risks were estimated using random effects meta-analysis techniques.
Results
Three studies (n = 204) met inclusion criteria. Patients were 42 ± 13 years of age and 51% female. Serotonin-specific reuptake inhibitors were found to substantially reduce the likelihood of a patient having at least one recurrence of vasovagal syncope [relative risk (RR) 0.34 (0.20–0.60), p < 0.01] with minimal between-study heterogeneity (I2 = 0%, p = 0.67). Serotonin-specific reuptake inhibitors in two reports provided significant protection against clinical presyncope [RR 0.43 (0.24–0.77), p < 0.01], with minimal between-study heterogeneity (I2 = 0%, p = 0.80).
Conclusions
Serotonin-specific reuptake inhibitors may be effective in preventing syncope induced by head-up tilt testing and in syncope in the community in randomized, double-blinded clinical trials.
Similar content being viewed by others
Data availability
Data will be provided following a reasoned request to the senior author.
References
Brignole M, Moya A, de Lange FJ et al (2018) 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J 39:1883–1948
Shen WK, Sheldon RS, Benditt DG et al (2017) 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 70:620–663
Ng J, Sheldon RS, Ritchie D, Raj V, Raj SR (2019) Reduced quality of life and greater psychological distress in vasovagal syncope patients compared to healthy individuals. Pacing Clin Electrophysiol 42:180–188
Ng J, Sheldon RS, Maxey C et al (2019) Quality of life improves in vasovagal syncope patients after clinical trial enrollment regardless of fainting in follow-up. Auton Neurosci 219:42–48
Sun BC (2013) Quality-of-life, health service use, and costs associated with syncope. Prog Cardiovasc Dis 55:370–375
van Dijk N, Sprangers MA, Boer KR, Colman N, Wieling W, Linzer M (2007) Quality of life within one year following presentation after transient loss of consciousness. Am J Cardiol 100:672–676
Rose MS, Koshman ML, Spreng S, Sheldon R (2000) The relationship between health-related quality of life and frequency of spells in patients with syncope. J Clin Epidemiol 53:1209–1216
Jorge J, Raj S, Liang Z, Sheldon R (2022) Quality of life and injury due to vasovagal syncope. Clin Auton Res 32:147–149
Jorge JG, Raj SR, Teixeira PS, Teixeira JAC, Sheldon RS (2021) Likelihood of injury due to vasovagal syncope: a systematic review and meta-analysis. Europace 23:1092–1099
Jorge JG, Pournazari P, Raj SR, Maxey C, Sheldon RS (2020) Frequency of injuries associated with syncope in the prevention of syncope trials. Europace 22:1896–1903
Sheldon R, Raj SR, Rose MS et al (2016) Fludrocortisone for the prevention of vasovagal syncope: a randomized, placebo-controlled trial. J Am Coll Cardiol 68:1–9
Lei LY, Raj SR, Sheldon RS (2022) Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis. Europace 24:1171
Sheldon R, Faris P, Tang A et al (2021) Midodrine for the prevention of vasovagal syncope: a randomized clinical trial. Ann Intern Med 174:1349–1356
Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A (1999) Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 33:1227–1230
Flevari P, Leftheriotis D, Repasos E, Katsaras D, Katsimardos A, Lekakis J (2017) Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. Europace 19:127–131
Theodorakis GN, Leftheriotis D, Livanis EG et al (2006) Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Europace 8:193–198
Sheldon R, Rose MS, Ritchie D et al (2019) Genetic association study in multigenerational kindreds with vasovagal syncope. Circ Arrhythm Electrophysiol 12:e006884
Schulz KF, Altman DG, Moher D, CONSORT Group (2010) Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010(8):18
Campagna JA, Carter C (2003) Clinical relevance of the Bezold-Jarisch reflex. Anesthesiology 98:1250–1260
Yamano M, Ito H, Kamato T, Miyata K (1995) Characteristics of inhibitory effects of serotonin (5-HT)3-receptor antagonists, YM060 and YM114 (KAE-393), on the von Bezold-Jarisch reflex induced by 2-methyl-5-HT, veratridine and electrical stimulation of vagus nerves in anesthetized rats. Jpn J Pharmacol 69:351–356
Tandan T, Giuffre M, Sheldon R (1997) Exacerbations of neurally mediated syncope associated with sertraline. Lancet 349:1145–1146
Sheldon RS, Gerull B (2021) Genetic markers of vasovagal syncope. Auton Neurosci 235:102871
Theodorakis GN, Markianos M, Livanis EG, Zarvalis E, Flevari P, Kremastinos DT (1998) Central serotonergic responsiveness in neurocardiogenic syncope: a clomipramine test challenge. Circulation 98:2724–2730
Theodorakis GN, Livanis EG, Leftheriotis D, Flevari P, Markianos M, Kremastinos DT (2003) Head-up tilt test with clomipramine challenge in vasovagal syndrome-a new tilt testing protocol. Eur Heart J 24:658–663
Leftheriotis DI, Theodorakis GN, Kremastinos DT (2003) Prolonged asystole during head-up tilt testing with clomipramine infusion. Europace 5:313–315
Theodorakis GN, Markianos M, Zarvalis E, Livanis EG, Flevari P, Kremastinos DT (2000) Provocation of neurocardiogenic syncope by clomipramine administration during the head-up tilt test in vasovagal syndrome. J Am Coll Cardiol 36:174–178
Funding
This work was unsupported.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Data collection was performed by all authors. Data analysis and the first draft of the manuscript was written by RS and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Raj, P., Lei, L., Flevaris, P. et al. Serotonin reuptake inhibition for the prevention of vasovagal syncope: a systematic review and meta-analysis. Clin Auton Res 33, 811–819 (2023). https://doi.org/10.1007/s10286-023-01000-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10286-023-01000-5